To reduce the possibility of compromising long-term protection mediated by tissue resident CD8+ T cells, the timing and location of B7-H1/PD-1 blockade as a therapy for virus vaccines or infection should be carefully optimized in order to support the generation and maintenance of a pool of antigen specific CD8+ TRM. The gene discussed is CD8A; the disease is infection.